Analyzing Early Clinical Evidence of Treg Modulation Across Healthy Volunteers & SLE Patients

9:00 am - Thursday 25th March 2027

  • Examining combined Phase I clinical data from healthy volunteers and SLE patients to build a comprehensive understanding of Treg-directed therapeutic activity
  • Revealing pharmacokinetic, pharmacodynamic, and disease activity findings to assess the translational potential of Treg modulation in autoimmune disease
  • Leveraging integrated clinical analyses to inform future development strategies and strengthen confidence in Treg-targeted approaches for SLE

Speakers:

Executive Vice President of Research & Development
Cugene Inc